Skip to main content
Premium Trial:

Request an Annual Quote

Sherlock Biosciences Licenses Ambient Temperature Amplification Tech From Wyss Institute

NEW YORK – Sherlock Biosciences said on Monday that it has licensed a nucleic acid amplification technology that functions at ambient temperatures from Harvard's Wyss Institute. Financial terms of the deal were not disclosed.

The exclusive worldwide license covers technology developed at Wyss in the lab of James Collins, developer of Sherlock's CRISPR-based core technology and a cofounder of the company.

Sherlock plans to combine the method with its CRISPR platform to develop instrument-free diagnostic tests to detect pathogen or disease-related nucleic acids at the point of need.

"The highly stable enzyme-based, multi-component nucleic acid amplification method coming out of Collins' Wyss lab will be a pivotal piece of our technology platform," said Bryan Dechairo, Sherlock's president and CEO, in a statement.

The Specific High-sensitivity Enzymatic Reporter unlocking, or SHERLOCK, technology detects target RNA or DNA molecules with high sensitivity and specificity, and without strict temperature requirements. "By integrating it with this next-generation amplification technology, we will be able to perform the entire detection-amplification-visualization process at ambient temperatures and, importantly, instrument-free," Dechairo added.

Sherlock Biosciences was founded in 2019 to build low-cost, portable diagnostic tests addressing critical unmet needs for patients at home and in low-resource settings using CRISPR and other technologies. Sherlock and the Collins lab have previously collaborated on point-of-care molecular malaria assays.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.